Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.10 +0.41 (+0.81%)
Streaming Delayed Price Updated: 10:26 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward. 
Via Stocktwits
Topics Death
News headline image
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
From Genentech
Via Business Wire
News headline image
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
News headline image
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' ↗
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate. 
Via Benzinga
News headline image
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround ↗
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock. 
Via Benzinga
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
News headline image
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
News headline image
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. ↗
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. 
Via Investor's Business Daily
Topics Government
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
News headline image
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
News headline image
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
 
Via Benzinga
News headline image
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits
News headline image
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data. 
Via Stocktwits
News headline image
Genentech Provides Update on Phase III Verona Study
From Genentech
Via Business Wire
News headline image
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause. 
Via Benzinga
Topics Death
News headline image
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
News headline image
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
News headline image
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
News headline image
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma ↗
Three new cancer drugs could help make a dent in the company's ambitious plans for 2030. 
Via Investor's Business Daily
News headline image
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
From Genentech
Via Business Wire
News headline image
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years ↗
Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.